Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2022-05-18 Major Shareholding Noti…
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding ('Holder', 'Instrument', 'Transaction', 'Shares', 'Voting rights') for Egetis Therapeutics AB. Specifically, it mentions 'Reason for major shareholding notification New share issue' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (8.2%). This structure is characteristic of a notification regarding a significant change in ownership, often triggered by crossing a threshold. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2022-05-18 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for a specific holder, RegulaPharm AB, concerning Egetis Therapeutics AB (publ). It explicitly states the 'Reason for major shareholding notification' as 'New share issue' and provides 'Before the transaction' and 'After the transaction' figures for shares and voting rights, including the resulting percentage (4.9%). This structure is characteristic of a notification regarding a change in significant ownership thresholds. Based on the provided definitions, this aligns perfectly with 'Major Shareholding Notification' (Code: MRQ). The document is a direct notification, not an announcement of a report (RPA/RNS).
2022-05-17 English
Egetis Therapeutics publishes prospectus relating to the Rights Issue
Capital/Financing Update Classification · 98% confidence The document is titled "Egetis Therapeutics publishes prospectus relating to the Rights Issue" and explicitly states that the prospectus, prepared in connection with a Rights Issue (a capital/financing activity), has been approved and registered by the Swedish Financial Supervisory Authority (SFSA) and is now available. The text itself is a press release announcing the publication of the prospectus, rather than the prospectus document itself. According to Rule 2, when a document is short and announces that a report (like a prospectus) is published or attached, it should be classified as a Report Publication Announcement (RPA). The content focuses on the announcement of the prospectus availability related to a capital raising event (Rights Issue). Therefore, RPA is the most appropriate classification.
2022-04-28 English
Egetis Therapeutics offentliggör prospekt avseende företrädesemissionen
Capital/Financing Update Classification · 98% confidence The document is a press release from Egetis Therapeutics AB dated April 28, 2022, announcing that the prospectus ('prospekt') related to a rights issue ('företrädesemissionen') has been approved and registered by the Swedish Financial Supervisory Authority ('Finansinspektionen'). The text explicitly states that the prospectus is now available on the company's and the financial advisor's websites. This document is not the comprehensive financial report (10-K or IR) itself, nor is it a general earnings release (ER). Instead, it is an announcement about the publication of a key offering document (the prospectus) related to a capital/financing activity (the rights issue). According to the definitions, documents announcing the publication of reports or offering documents often fall under RPA or RNS. Since this announcement is specifically about the publication of a prospectus related to a capital raise, the most fitting category is Capital/Financing Update (CAP) or Report Publication Announcement (RPA). Given the core subject is the financing event (rights issue) and the publication of the associated legal document (prospectus), CAP is highly relevant, but RPA specifically covers the announcement of a report/document publication. Since the document's primary function is to announce the availability of the prospectus for the rights issue, and it is a formal announcement, RPA (Report Publication Announcement) is a strong fit, as it signals the release of a major document. However, since the underlying event is a capital raise, CAP (Capital/Financing Update) is also very relevant. Given the explicit mention of 'Publicering av prospekt' (Publication of prospectus) and the nature of the document being a press release announcing the availability of the prospectus, RPA is the most precise classification for the *type of announcement* being made, even though the subject matter is capital raising. I will select CAP as the primary driver is the financing activity being detailed via the prospectus, which is a core component of a CAP filing, and the document itself is the announcement of that financing structure's key document.
2022-04-28 Swedish
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Kallelse till årsstämma' (Notice of Annual General Meeting) for Egetis Therapeutics AB. It contains the agenda, proposals for board elections, remuneration guidelines, and instructions for shareholders to participate via proxy/advance voting. This document is a solicitation of shareholder action and information for an upcoming meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-04-28 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-March 2022. It contains comprehensive financial statements, a management review (VD har ordet), details on R&D projects, and operational updates. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-26 Swedish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.